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A B S T R A C T
We demonstrate a homogeneous biosensor for the detection of multivalent targets by combination of magnetic
nanoparticle (MNP) chains and a low-cost 405 nm laser-based optomagnetic system. The MNP chains are
assembled in a rotating magnetic ﬁeld and stabilized by multivalent target molecules. The number of chains
remaining in zero ﬁeld is proportional to the target concentration, and can be quantiﬁed by optomagnetic
measurements. The shape anisotropy of the MNP chains enhances the biosensor system in terms of providing
eﬃcient mixing, reduction of depletion eﬀects (via magnetic shape anisotropy), and directly increasing the
optomagnetic signal (via optical shape anisotropy). We achieve a limit of detection (LOD) of 5.5 pM (0.82 ng/
mL) for the detection of a model multivalent molecule, biotinylated anti-streptavidin, in PBS. For the
measurements of prostate-speciﬁc antigen (PSA) in 50% serum using the proposed method, we achieve an
LOD of 21.6 pM (0.65 ng/mL) and a dynamic detection range up to 66.7 nM (2 µg/mL) with a sample-to-result
time of approximately 20 min. The performance for PSA detection therefore well meets the clinical
requirements in terms of LOD (the threshold PSA level in blood is 4 ng/mL) and detection range (PSA levels
span from < 0.1–104 ng/mL in blood), thus showing great promise for routine PSA diagnostics and for other
in-situ applications.
1. Introduction
Due to their large surface-to-volume ratio, simplicity of bio-
functionalization, low background signal in biological samples, and
cost-eﬃciency, magnetic particles have been widely used in biosensors
ranging from in-situ decentralized diagnostics to centralized laboratory
based high-throughput assays (Lee et al., 2015; Tekin and Gijs, 2013).
Manipulated by external magnetic ﬁelds (static or dynamic actuation),
magnetic particles have long been utilized for extraction, enrichment
and stirring (mixing) to accelerate the reaction kinetics and improve
the sensitivity of biosensors (van Reenen et al., 2014). In particular, the
application of a rotating magnetic ﬁeld (RMF) can induce formation of
one-dimensional nanostructured assemblies of magnetic particles
(Vuppu et al., 2003). The rotation of the formed magnetic particle
chains results in eﬀective mixing and accelerates reactions that are
otherwise limited by diﬀusion (Fermigier and Gast, 1992; Martin et al.,
2009). Moreover, the angular velocity of the magnetic particle chains
reduces the depletion layers of target molecules around the particles,
thereby increasing the association constant of the reaction (van Reenen
et al., 2017).
Magnetic ﬁeld-induced particle chains can be stabilized by the
binding of multivalent molecules (Furst et al., 1998; Goubault et al.,
2005). The relationship between the concentration of multivalent
molecules and the shape anisotropy of the chains has been utilized to
design RMF-based biosensors (Park et al., 2010a, 2010b; Ranzoni
et al., 2011; Vuppu et al., 2004). These RMF and chain formation based
biosensors analyze the transmitted (or scattered) laser light to quantify
the target molecules in the sample. Park et al. (2010a) reported an
RMF-based optomagnetic biosensor to monitor the changes of the
transmitted laser light intensity at diﬀerent angles between the
direction of the magnetic chains and that of the light, thereby achieving
a limit of detection (LOD) of 100 pM avidin. Ranzoni et al. measured
the scattered light from particle dimers and achieved an LOD of 5 pM
biotinylated BSA in serum (Ranzoni et al., 2011). However, some other
important properties of the suspension, such as the hydrodynamic size
of the chains and the concentration of unbound magnetic particles,
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were not monitored due to the design of the sensors and the utilization
of superparamagnetic particles. Therefore, these optomagnetic biosen-
sors have limited linear detection ranges (no more than 3 orders of
magnitude) and lack the potential for multiplexing. In addition, both of
these works only demonstrated the capability of their biosensors with
biotin-avidin/streptavidin model reaction systems, which are much
stronger and faster than common biological reactions.
The 405 nm laser-based optomagnetic sensor, ﬁrst reported by
Donolato et al. (2015a), is a rapid and low-cost volumetric magnetic
nanoparticle (MNP) detection system that provides information about
the hydrodynamic size of suspended MNPs. By measuring the alter-
nating current (AC) magnetic ﬁeld-induced modulation of the optical
transmission signal, this optomagnetic sensor has been utilized to
detect a variety of analytes including proteins (Antunes et al., 2015;
Fock et al., 2017b; Uddin et al., 2016), bacteria (Tian et al., 2016a),
microRNA (Tian et al., 2017), DNA (Minero et al., 2017), and
amplicons of diﬀerent DNA ampliﬁcation methods (Donolato et al.,
2015b; Mezger et al., 2015; Tian et al., 2016b). In previous work,
magnetic incubation was employed to accelerate the formation of MNP
clusters having a random morphology and to minimize nonspeciﬁc
binding between MNPs (Uddin et al., 2016). The magnetic incubation
was performed by incubating and shaking the samples between two
magnets (Baudry et al., 2006; Daynes et al., 2015; Ranzoni et al.,
2012). The linear detection range for these magnetic cluster-based
optomagnetic biosensors is around 2 orders of magnitude, which is
relatively good but not enough for clinical quantitative analysis.
Herein, for the ﬁrst time, we demonstrate a shape anisotropy
enhanced protein bioassay using the 405 nm laser-based optomagnetic
setup. Recognition molecule coated MNPs are mixed with multivalent
target proteins and incubated in an external RMF. Induced by the RMF
and stabilized by the binding of target proteins, MNP chains can be
quantiﬁed after incubation. The shape anisotropy of magnetic chains
enhances the AC magnetic ﬁeld-induced modulation of the optical
transmission, and leads to an increase of the signal amplitude (and
accuracy) compared to previous work, which does not utilize this shape
anisotropy (Antunes et al., 2015). We demonstrate the detection
principle by analysis of a model protein, biotinylated anti-streptavidin,
with streptavidin coated 250 nm MNPs. The signal of the MNP chains
presents in the low-frequency region of the optomagnetic spectrum and
is used to detect low target concentrations. We also determine the
concentration of unbound MNPs by monitoring the high-frequency
region of the optomagnetic spectrum. Since the reduction of the
concentration of unbound MNPs upon chain formation is not inﬂu-
enced by the size or shape of the aggregates that are formed, the signal
from unbound MNPs can be used to detect high target concentrations,
thereby extending the linear detection range of the assay.
Prostate-speciﬁc antigen (PSA), a serine protease indicator that
relates to many prostate diseases including prostate cancer of all grades
and stages, is widely detected as a cancer biomarker both for initial
diagnosis and for monitoring the response to treatment (Lilja et al.,
2008). PSA levels span from < 0.1–104 ng/mL in blood and the
median PSA level for healthy adult males aged ≤ 50 years is
approximately 0.6 ng/mL (Savblom et al., 2005). The traditional
threshold PSA level (in blood) for detecting prostate cancer is 4 ng/
mL, and levels above 102 ng/mL have been found almost exclusively
related to advanced prostate cancer (Lilja et al., 2008). The low
threshold level and large concentration span of PSA require detection
methods with both high sensitivities and wide detection ranges, which
is challenging especially for in-situ diagnostics. Furthermore, analysis
of a single biomarker may give misleading diagnostic results for
prostate cancer detection (Harris and Lohr, 2002), meaning that the
capability for multiplex detection of PSA and other biomarkers is
important for biosensors. To demonstrate the applicability of the shape
anisotropy enhanced optomagnetic sensor for in-situ clinical applica-
tions, we evaluate our biosensor for the detection of serum samples
spiked with PSA.
2. Materials and methods
2.1. Reagents
Ultrapure grade phosphate buﬀered saline (PBS, 20 ×) and bovine
serum albumin (BSA) were purchased from AMRESCO (Solon, USA).
Biotinylated goat anti-streptavidin antibody was purchased from
Vector Laboratories Inc. (Burlingame, USA). Native human PSA
(30 kDa), polyclonal sheep anti human PSA, and biotin conjugation
kit (type 2) were purchased from Bio-Rad Laboratories (Kidlington,
UK). Streptavidin coated 250 nm MNPs (multicore magnetic beads
containing clusters of small single domain particles, product code 09-
19-252, 10 mg/mL, 4.9 × 1011 particles/mL) were purchased from
Micromod (Rostock, Germany). Fetal bovine serum was purchased
from Sigma-Aldrich (St. Louis, USA). UV-transparent cuvettes (REF
67.758.001) for optomagnetic measurements were purchased from
SARSTEDT (Nümbrecht, Germany). Particles and biotinylated anti-
streptavidin were suspended or diluted in 1 × PBS containing 0.1%
(1 mg/mL) BSA.
2.2. Antibody conjugation of MNPs
The polyclonal sheep anti-PSA antibody was biotinylated using the
biotin conjugation kit according to the instructions provided by the
manufacturer. Antibody-conjugated 250 nm MNPs were prepared by
adding 100 µg of biotinylated sheep anti-PSA antibody into 0.1 mL of
250 nm streptavidin coated MNPs (10 mg/mL, 1.5–2 µg streptavidin/
mg MNP) followed by incubation at room temperature for 1 h. After
washing three times with PBS using a magnetic stand, the Ab-MNPs
were resuspended at a concentration of 1 mg/mL in PBS (containing
0.1% BSA) and stored at 4 °C.
2.3. RMF incubation platform and optomagnetic setup
The RMF platform contains a pair of computer-controlled, perpen-
dicular iron-core magnetic circuits that can generate a homogeneous
magnetic ﬁeld in the central part of the platform. The chain formation
process in an RMF was observed using an Olympus BX60 microscope
equipped with a 10× objective and a digital camera, and images were
analyzed using the public domain Java image processing software
ImageJ (Bejhed et al., 2015; Schneider et al., 2012). For the optomag-
netic setup, a detailed description as well as the underlying theory can
be found in our previous publications (Fock et al., 2017a; Tian et al.,
2017). Brieﬂy, an AC magnetic excitation ﬁeld, H t H πft( ) = sin(2 )0 , with
H0 = 2.1 kA/m was applied parallel to the laser beam (λ = 405 nm, a
light beam diameter of 2 mm), and the optical path through the cuvette
was 10 mm. The real (sin(4πft) part of the second harmonic component
of the transmitted light intensity, V′2, was recorded and normalized
with respect to the simultaneously measured total intensity of trans-
mitted laser light, V0, to compensate for the variations in laser light
intensity, particle concentration and cuvette reﬂection/absorption.
2.4. Reaction and optomagnetic measurement
Streptavidin coated MNPs and anti-PSA antibody-conjugated
MNPs were utilized for the detection of biotinylated anti-streptavidin
and PSA, respectively. The sample (95 µL) was mixed with 5 µL of bio-
functionalized 250 nm MNPs to a ﬁnal MNP concentration of 50 µg/
mL (4.07 fM), followed by incubation at room temperature in the RMF
platform. A rotational frequency of 1 Hz was applied. For plotting dose-
response curves of biotinylated anti-streptavidin and PSA, the incuba-
tion time was 15 min and the RMF strength, HRMF, was 10 kA/m.
Thereafter the suspension was measured by the optomagnetic setup.
Twenty-ﬁve logarithmically equidistant frequency points were recorded
in the frequency range of 0.3–100 Hz, and the data acquisition time
was 270 s. The cutoﬀ value was calculated as the average value
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(measured at 1.3 Hz or 18.4 Hz) of the blank control samples minus
three standard deviations, and the LOD was obtained based on the 3σ
criterion.
2.5. Measurement of static magnetization curves
A hysteresis loop starting with a virgin curve was measured at
300 K in the ﬁeld range −60–60 kA/m for a 10 mg/mL suspension of
the non-conjugated MNPs adsorbed and dried on cotton wool. For this,
an MPMS-XL SQUID magnetometer (Quantum Design, USA) was
used.
2.6. Scanning electron microscopy characterization
The morphology and nanostructure of dispersed 250 nm MNPs
(MNPs are of multicore type, i.e., built up of a clusters of small single
domain particles) and MNP chains were characterized by scanning
electron microscopy (SEM, Zeiss-1530) using an in-lens detector for
secondary electrons and the microscope was operated at 10 kV electron
beam accelerating voltage.
3. Results and discussion
3.1. Principle of the shape anisotropy enhanced optomagnetic
biosensor
The principle of the shape anisotropy enhanced optomagnetic
sensor is illustrated in Fig. 1. A video, provided as Supplementary
material, illustrates the setup and detection principle. The functiona-
lized 250 nm MNPs form dipolar chains in the presence of the RMF
and are subsequently stabilized in presence of the multivalent target.
The RMF is turned oﬀ after a short incubation period to allow non-
stabilized chains to disassemble. In the absence of multivalent target
molecules, the magnetic chains quickly dissociate during the optomag-
netic measurement and correspondingly the optomagnetic spectrum
contains only the signal from unbound MNPs. In the presence of
multivalent target molecules, the optomagnetic spectrum contains
contributions from both unbound MNPs and target-stabilized MNP
chains. The characteristic valley/peak positions in the optomagnetic
V V′ /2 0 spectra are related (but not equal) to the Brownian relaxation
frequencies of the particles (Fock et al., 2017a). For particles in liquid,
the characteristic frequency for Brownian relaxation is given by
f k T πηV= /(6 ),B B h
where kBT is the thermal energy, η is the viscosity and Vh is the mean
hydrodynamic volume of the particle. Target molecules captured by the
chains can be quantiﬁed by measuring the V V′ /2 0 spectra of the
suspension. A typical V V′ /2 0 spectrum in this study is characterized by
a valley in the low-frequency region that represents the response of
target-stabilized chains (if present), and a peak in the high-frequency
region that represents the unbound MNPs. The sign changes of the
characteristic peaks (valleys) are caused by the dependence of the
optical extinction coeﬃcient on the sizes of MNPs and chains (Fock
et al., 2017b). Target quantiﬁcation can be accomplished by monitoring
either the valley or peak amplitudes.
Supplementary material related to this article can be found online
at doi:10.1016/j.bios.2017.06.062.
Fig. 1. Schematic illustration of the shape anisotropy enhanced optomagnetic biosensor. The assay includes two independent steps: incubation in an RMF and optomagnetic
measurement. Gray and red arrows indicate the assay steps of a blank control sample (the left panels) and of a positive sample (the right panels), respectively. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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3.2. Optimization of the assay
During the incubation step in the RMF platform, magnetic chains
rotate in-phase with the RMF. This gives rise to a stirring of the ﬂuid
that accelerates the reaction speed of the homogeneous assay. The
formation of chains of superparamagnetic MNPs can be described by
the dimensionless Mason number (Mn) which considers both the
rotational shear force and the magnetic interaction force (Melle and
Martin, 2003; Petousis et al., 2007):
F
F
ηω
μ χ H
Mn ≡ ≈ 16 ,H
m 0
2
RMF
2
where ω is the angular rotation frequency of the RMF, μ0 is the
permeability of free space, and χ is the eﬀective magnetic susceptibility
of the MNPs. As shown by the magnetization curve (Fig. S1 in
Supplementary material) measured at 300 K for non-conjugated
250 nm MNPs (concentration 10 mg/mL, particles adsorbed and dried
in cotton wool), the particles have an approximately superparamag-
netic linear behavior (with a small remanence) for ﬁelds up to 60 kA/
m, and therefore the above expression for the Mason number is
qualitatively valid for our study. There is a positive correlation between
the average length and HRMF, since the average number of MNPs in a
stable chain can be described by (Petousis et al., 2007)
Fig. 2. Observation of magnetic chains in an optical microscope. (a)–(e) Representative top-view images of magnetic chains formed in diﬀerent HRMF. (f) Eﬀect of HRMF on the average
chain length. Error bars indicate the standard deviation of the average chain lengths for four diﬀerent images.
Fig. 3. (a) Relationship between V V′ /2 0 valley amplitude (measured at 1.3 Hz) and logarithm of model target (biotinylated anti-streptavidin) concentration at diﬀerent HRMF (5, 10, 20,
40 and 60 kA/m). Error bars indicate the standard deviation of three independent replicates. (b) Representative SEM micrograph of dispersed MNPs. (c) Representative SEM
micrograph of magnetic chains formed at HRMF = 10 kA/m (the concentration of biotinylated anti-streptavidin is 6.7 nM).
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N ≈ Mn .−0.5
The binding force induced by the multivalent target molecules,
Fbinding, can decrease the Mason number (Park et al., 2010a), then
F F FMn ≡ /( + )H m binding . Therefore the average chain length is increased
due to the binding force.
The average chain length versus ﬁeld amplitude was investigated in
the RMF platform (Fig. 2). Following optimization routines reported
elsewhere (Ranzoni et al., 2011), a rotation frequency of 1 Hz was
chosen for the RMF; while HRMF was set to 5, 10, 20, 40 and 60 kA/m
(Fig. 2a to Fig. 2e). For each of the ﬁve diﬀerent HRMF, four images
(corresponding to four randomly selected places) were taken. The
average chain length was calculated for each image. The mean value
and the standard deviation of the four average chain lengths for the
four diﬀerent images were calculated for each HRMF (Fig. 2f).
We argue that the target-mediated stabilization of chains occurs
mainly in two ways: (1) a multivalent molecule reaches the junction
area between two MNPs and forms a sandwich structure; and (2) a
multivalent molecule captured on the surface of one MNP encounters
another MNP and forms a sandwich structure. The ﬁrst type of
stabilization eﬀect can be enhanced by forming longer chains (provid-
ing more junction areas, which need high HRMF), increasing the
particle velocities (particle actuation can resolve the limitations of
depletion eﬀects), and stirring of the ﬂuid (convection). The second
stabilization type is favored for shorter chains. Provided that MNPs in
the same chain have ﬁxed positions relative to each other, the second
type of sandwich formation mainly occurs at the terminal MNPs of the
chain during the repeatedly breaking and reforming of magnetic
chains. For a certain MNP concentration, a higher HRMF induces
longer chains, leading to fewer terminal MNPs and less stabilization
of the second type. From this we argue that there exists an optimum
HRMF for chain stabilization and for assay performance. Increasing the
concentration of MNPs is not considered in this study since it will
decrease the sensitivity of the method (Tian et al., 2016c). Additionally,
a too high HRMF leads to the formation of large MNP clusters, which
are undetectable in the current optomagnetic setup, since their
response fall below the detection frequency window.
In order to optimize the RMF parameters, biotinylated anti-
streptavidin was used as a model multivalent target molecule to
stabilize magnetic chains formed by streptavidin coated MNPs.
Biotinylated anti-streptavidin of diﬀerent concentrations was mixed
with streptavidin coated MNPs and incubated in an RMF for 10 min at
room temperature followed by optomagnetic measurement. The V V′ /2 0
valley amplitude at 1.3 Hz, which represents the response from
magnetic chains, was recorded at diﬀerent HRMF and plotted against
the target concentration to obtain an optimum HRMF (Fig. 3a). Due to
the formation and sedimentation of large MNP clusters formed at high
HRMF, V V′ /2 0 amplitudes of high target concentration samples incu-
bated at 40 and 60 kA/m do not represent magnetic chains and have
not been plotted. From Fig. 3a it can be concluded that the optimum
HRMF is around 10 kA/m, therefore a HRMF of 10 kA/m was applied in
subsequent experiments. The optimum HRMF is caused by a balance
between the two stabilization eﬀects discussed above.
The morphology of dispersed 250 nm MNPs (built up of clusters of
small single domain particles) and MNP chains was characterized by
SEM. Representative micrographs are shown in Fig. 3b and c,
respectively. Due to the multicore nanostructure as well as due to
drying eﬀects, it is diﬃcult to get any information about the uniformity
of the 250 nm MNPs. However, aggregated by 6.7 nM of biotinylated
anti-streptavidin in the RMF (HRMF = 10 kA/m), magnetic chains have
a clear shape anisotropy compared with dispersed 250 nmMNPs. Since
we were unable to perform SEM characterization in the presence of an
applied RMF, chains observed in SEM micrographs are much shorter
than those in Fig. 2b due to the breakup of magnetic dipolar bindings.
3.3. Quantitative detection of the model target in PBS
Under optimized experimental conditions (RMF of 1 Hz, 10 kA/m),
quantitative detection of the model target molecule was investigated.
Serial dilutions of biotinylated anti-streptavidin, ranging from 66.7 nM
(10 µg/mL) to 1 pM (150 pg/mL), were reacted with streptavidin
coated MNPs followed by optomagnetic measurements. From the
V V′ /2 0 spectra shown in Fig. 4a it can be seen that the valley (measured
at 1.3 Hz) and peak (measured at 18.4 Hz) amplitude increases and
decreases, respectively, with increasing target concentration. A typical
V V′ /2 0 spectrum is characterized by a valley located at around 1.3–
1.6 Hz, which represents the stabilized magnetic chains and a peak
located at around 14–18 Hz which represents the unbound MNPs. The
characteristic valley and peak positions were slightly shifted due to the
increase of chain length and the small overlap between the spectra of
unbound MNPs and magnetic chains. Interestingly, the hydrodynamic
size of the magnetic chains only slightly increased with increasing
target concentration, meaning that the increase of the V V′ /2 0 amplitude
at 1.3 Hz was mainly caused by the increasing amount of magnetic
chains but not by the increase of the chain length. The dose-response
curve for biotinylated anti-streptavidin is shown in Fig. 4b. A linear
correlation between the V V′ /2 0 valley amplitude and the target con-
centration can be observed between 1 and 260 pM (see inset in Fig. 4b)
with an average coeﬃcient of variation (CV) of 7.4% and an LOD of
5.5 pM obtained according to the 3σ criterion.
As a control experiment, detection of biotinylated anti-streptavidin
was performed without RMF, and the results are presented in Fig. 4b
(blue squares). Without RMF, the V V′ /2 0 signal at 1.3 Hz is low for all
Fig. 4. V V′ /2 0 spectra (a) and dose-response curves (b)–(c) for shape anisotropy enhanced optomagnetic detection of biotinylated anti-streptavidin in PBS. Valley (measured at 1.3 Hz)
and peak (measured at 18.4 Hz) amplitudes of the V V′ /2 0 spectra are plotted against the target concentration in panels b and c, respectively. Black lines in panel c and inset of panel b
show the linear detection range. Error bars indicate the standard deviation of three independent replicates. (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.)
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target concentrations (from 16.3 pM to 66.7 nM). This is caused by
depletion eﬀects as well as the slow diﬀusion of MNPs in conventional
(without RMF) particle-based capture experiments (van Reenen et al.,
2017). The transport of targets across the local concentration gradient
is dominated by diﬀusion when the particles are at low velocities. The
result is in good agreement with a previous study based on magnetic
incubation (Antunes et al., 2015).
The V V′ /2 0 value at 18.4 Hz, which represents the concentration of
unbound MNPs in the suspension, could also be utilized for indirect
monitoring of the chain formation reaction (see Fig. 4c). Although the
sensitivity of this turn-oﬀ detection format is comparatively low, a
linear correlation between the V V′ /2 0 peak amplitude (measured at
18.4 Hz) and logarithm of target concentration is observed between
260 pM and 66.7 nM (the black line in Fig. 4c) with an average CV of
3.7%. Considering that the reduction of the V V′ /2 0 value at 18.4 Hz is
not aﬀected by the size or shape of the MNP aggregates, the saturation
concentration for V V′ /2 0 at 18.4 Hz is much higher than the corre-
sponding value at 1.3 Hz. Therefore, monitoring the concentration of
unbound MNPs can be used to detect high target concentrations when
the signal at 1.3 Hz is approaching saturation. By combining the turn-
on and turn-oﬀ read-outs presented in Fig. 4, we have demonstrated a
two-section linear detection range of approximately four orders of
magnitude (from 1 pM to 66.7 nM). Note that for the low-concentra-
tion section, the signal is linear with target concentration, whereas, for
the high-concentration section, the signal is linear with the logarithm
of target concentration. In addition, since MNPs of diﬀerent sizes have
diﬀerent characteristic valley/peak frequencies, MNPs of diﬀerent sizes
can be coated with diﬀerent antibodies for detecting diﬀerent bio-
macromolecules simultaneously. This means that the proposed bio-
sensor has the potential for multiplex biosensing which cannot be
achieved by other optomagnetic biosensors that only monitor the
chains.
3.4. Quantitative detection of PSA in serum
Blood analysis of PSA is performed for initial diagnosis and for
monitoring response to treatment. However, it is challenging to per-
form assays in complex biological matrices due to matrix eﬀects. Here
we analyze PSA spiked in fetal bovine serum to demonstrate the
applicability of our biosensor for detection in biological matrixes. Fetal
bovine serum has three main eﬀects that may inﬂuence the assay: (1)
inducing aggregation of MNPs, (2) inhibiting the immuno-reaction and
(3) increasing the viscosity of the suspension. In previous work, the
aggregation eﬀect was evaluated (Tian et al., 2017), and here we chose
50% serum to avoid signiﬁcant aggregation. The higher viscosity of the
serum inﬂuences both the Mason number and the Brownian relaxation
frequency of MNPs and chains, which could reduce the sensitivity of
the system.
Fig. 5a showsV V′ /2 0 at 1.3 Hz as a function of RMF incubation time.
For the detection of 1 nM of PSA spiked in 50% serum (the concentra-
tion of PSA is lower than the surface concentration of antibodies on
MNPs), the signal increased dramatically during the ﬁrst 9 min. After
that, non-speciﬁc bindings were gradually replaced by antibody-anti-
gen bindings, resulting in a slight increase of the signal. For the
detection of 16.7 nM of PSA spiked in 50% serum (the concentration of
PSA is much higher than the surface concentration of antibodies on
MNPs), the signal kept increasing during the measurement, suggesting
that a longer incubation time is needed to reach the signal saturation
level for higher target concentrations. Considering that an incubation
time of 15 min is enough to reach a saturation signal level for samples
of low target concentrations, prolonging the incubation time can hardly
improve the sensitivity of the system. Therefore, we chose 15 min as
the incubation time to provide a universal biosensing system.
TheV V′ /2 0 spectra and dose-response curve of PSA detection in 50%
serum are shown in Fig. 5b–c, respectively. The result shows that
detection of PSA in 50% serum samples can be achieved with an LOD
of 21.6 pM (0.65 ng/mL) according to the 3σ criterion and with a
dynamic range up to 66.7 nM (2 µg/mL). The average CV is 5.9%. The
sample-to-answer time of PSA detection in serum is approximately
20 min including 15 min for incubation in the RMF and 4.5 min for
measurement. The matrix eﬀects do not have an obvious inﬂuence on
the valley/peak positions or on the shape of the spectra. Considering
that serum contains a high concentration of background bio-macro-
molecules, we did not perform further investigations on the speciﬁcity
of the proposed biosensor.
The proposed biosensor system has several advantages compared
with magnetic cluster-based 405 nm-laser optomagnetic sensors.
Firstly, the RMF and the magnetic chains induce eﬃcient mixing and
thereby overcome the limitations imposed by target diﬀusion.
According to the theory of actuated particle capture and target
depletion zone (van Reenen et al., 2017), applying an RMF can achieve
a higher capture eﬃciency than applying a static ﬁeld or a ﬁeld gradient
only. However the accelerating eﬀect is diﬃcult to quantify due to the
end-point detection format employed in the current work. Secondly,
the shape anisotropy enhances the V V′ /2 0 signal amplitude, thus
increasing the accuracy of measurement. Lastly, by combining the
turn-on magnetic chain measurement (monitoring V V′ /2 0 at low
frequency) with the turn-oﬀ unbound MNP measurement (monitoring
V V′ /2 0 at high frequency), a two-section linear detection range of
approximately four orders of magnitude has been achieved, which is
much wider than for previous immuno-optomagnetic biosensors.
Another PSA detecting optomagnetic biosensor, reported by Ranzoni
et al. (2012), measured the scattered light from oscillating magnetic
ﬁeld-induced particle dimers and achieved an LOD of 0.5 pM with a
dynamic detection range of 0.5–200 pM (0.015–6 ng/mL). Although
our biosensor in comparison with Ranzoni et al. (2012) is less sensitive
Fig. 5. Eﬀect of RMF incubation time (a), V V′ /2 0 spectra (b) and dose-response curve (c) for shape anisotropy enhanced optomagnetic detection of PSA in 50% serum. Error bars
indicate the standard deviation of three independent replicates.
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due to the lack of dimer detection capability, our LOD for PSA
(0.65 ng/mL) is still well below the clinical threshold PSA level in
blood (4 ng/mL). In addition, our biosensor provides a wider detection
range (up to 2 µg/mL) that is comparable to the clinical concentration
range of PSA in blood (up to 10 µg/mL).
4. Conclusion
In summary, we have demonstrated a rapid biosensor principle for
bio-macromolecule detection utilizing ﬁeld-assembly of dipolar mag-
netic chains and shape anisotropy enhanced optomagnetic technology.
The formation of particle chains enhances the biosensor system by
mixing (convection) and increasing the optomagnetic signal. Our
method allows for the simultaneous detection of MNP chains and
unbound MNPs. We have optimized and tested the proposed biosensor
by quantifying a multivalent model protein, biotinylated anti-strepta-
vidin, in PBS. Thereafter the biosensor was further evaluated for
detection of PSA spiked in 50% serum, for which an LOD of 21.6 pM
(0.65 ng/mL) was achieved with a dynamic detection range up to
66.7 nM (2 µg/mL). The performance of our biosensor for PSA
detection therefore well meets the clinical requirements in terms of
LOD (the threshold PSA level in blood is 4 ng/mL) and detection range
(PSA levels span from < 0.1–104 ng/mL in blood). The detection
volume is 100 µL and the sample-to-answer time is approximately
20 min. On the basis of the two protein detection studies, we have
shown that the shape anisotropy enhanced optomagnetic biosensor is
rapid and sensitive enough for in-situ PSA diagnostics and other
clinical detections of multivalent molecules. Simultaneous detection
of diﬀerent biomarkers is one of our future topics, which can be
achieved by monitoring both chains and unbound MNPs of diﬀerent
sizes. In addition, by performing the measurement on a microﬂuidic
disc (Donolato et al., 2015b), the detection volume can be reduced to a
few microliters and the biosensor can enable a detection format close to
real-time, which will be another topic for future work.
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